Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE versus PROMETHEGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE versus PROMETHEGAN.
PROMETHAZINE HYDROCHLORIDE vs PROMETHEGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, exerting antihistaminic, sedative, antiemetic, anticholinergic, and local anesthetic effects. Its antiemetic effect is mediated via blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
IV: 25-50 mg every 4-6 hours; IM: 25-50 mg every 4-6 hours; PO: 25-50 mg every 4-6 hours; PR: 25-50 mg every 4-6 hours; Maximum: 300 mg/day.
None Documented
None Documented
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Terminal elimination half-life: 9-16 hours in adults, with an average of 12 hours. In children, half-life may be shorter (6-9 hours). Clinical context: dosing interval typically every 8-12 hours; accumulation possible with repeated dosing.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Primarily renal (urinary) as conjugated metabolites; about 70-80% of a dose is excreted in urine within 48 hours. Small amounts appear in feces via biliary elimination (approximately 5-10%).
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine